AR047729A1 - Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) - Google Patents

Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)

Info

Publication number
AR047729A1
AR047729A1 ARP040104408A ARP040104408A AR047729A1 AR 047729 A1 AR047729 A1 AR 047729A1 AR P040104408 A ARP040104408 A AR P040104408A AR P040104408 A ARP040104408 A AR P040104408A AR 047729 A1 AR047729 A1 AR 047729A1
Authority
AR
Argentina
Prior art keywords
apoe
therapeutic antibodies
apolipoprotein
antibody
binds
Prior art date
Application number
ARP040104408A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR047729A1 publication Critical patent/AR047729A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Un anticuerpo o fragmento de anticuerpo humano, donde dicho anticuerpo o fragmento: i) se une a un polipéptido que tiene la secuencia de aminoácidos que se muestra en la SEQ ID No..: 1 del dominio C-terminal de la apolipoproteína E (ApocE-CTD) o la secuencia de aminoácidos de una parte de la misma; y ii) se une a placas humanas. Polinucleotidos, vectores que los comprenden, células huésped, así como composiciones farmacéuticas y su uso en métodos diagnostico de trastornos amiloides.
ARP040104408A 2003-11-28 2004-11-26 Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) AR047729A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52517403P 2003-11-28 2003-11-28

Publications (1)

Publication Number Publication Date
AR047729A1 true AR047729A1 (es) 2006-02-15

Family

ID=33564077

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104408A AR047729A1 (es) 2003-11-28 2004-11-26 Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)

Country Status (16)

Country Link
US (1) US8058016B2 (es)
EP (2) EP1687336A2 (es)
JP (1) JP4869074B2 (es)
KR (2) KR20120108061A (es)
CN (1) CN1890266B (es)
AR (1) AR047729A1 (es)
AU (1) AU2004293180B2 (es)
BR (1) BRPI0417023A (es)
CA (1) CA2547675A1 (es)
GB (1) GB2408508A (es)
IL (1) IL175608A0 (es)
NO (1) NO20063026L (es)
RU (1) RU2006122946A (es)
TW (1) TW200530267A (es)
UY (1) UY28641A1 (es)
WO (1) WO2005051998A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004299486B2 (en) 2003-12-15 2011-05-19 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200844110A (en) * 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
CA2680564C (en) 2007-03-12 2018-05-01 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
WO2009000099A2 (en) * 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
DK2164961T3 (en) 2007-06-25 2015-03-02 Esbatech Alcon Biomed Res Unit Sequence based forward position and optimization of single chain ​​antibodies
US8173130B2 (en) 2007-09-05 2012-05-08 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
MX364200B (es) * 2008-04-09 2019-04-16 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
MX2013006116A (es) * 2010-12-02 2013-10-17 Univ Washington Tratamiento de sintomas asociados a placa amiloide.
CN102863525B (zh) * 2011-07-04 2014-06-04 武汉大学 一种重组人apoE拟肽及制备方法和应用
PL3021869T3 (pl) 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT
JP6861418B2 (ja) 2015-09-02 2021-04-28 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
KR20200087283A (ko) 2015-09-25 2020-07-20 제넨테크, 인크. 항-tigit 항체 및 이의 이용 방법
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
EP3597222A1 (en) * 2018-07-16 2020-01-22 Easemedcontrol R & D GmbH & Co KG Treatment and diagnosis of unresolved inflammatory diseases
US20220119502A1 (en) * 2019-02-28 2022-04-21 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
EP3757121A1 (en) * 2019-06-28 2020-12-30 Eisai R&D Management Co., Ltd. Apolipoprotein e fragments
MX2022011982A (es) * 2020-03-27 2022-12-15 Epivax Inc Epitopos de celulas t reguladoras.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE625212T1 (de) * 1992-10-13 2000-11-02 Univ Durham Verfahren zum entdecken von krankheit von alzheimer.
US6107045A (en) 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6046381A (en) 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
JP2002530122A (ja) 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
CA2426030C (en) 2000-11-03 2013-12-31 The J. David Gladstone Institutes Methods of treating disorders related to apoe
AU2002222308A1 (en) * 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular response
WO2003031971A1 (fr) * 2001-10-04 2003-04-17 Immuno-Biological Laboratories Co., Ltd. Reactif pour detecter un facteur de risque de la maladie d'alzheimer, necessaire de detection a cet effet, et procede de detection du facteur de risque de la maladie d'alzheimer au moyen de ce necessaire
WO2004011943A1 (en) * 2002-07-30 2004-02-05 The Regents Of The University Of California Method of diagnosing alzheimer's disease

Also Published As

Publication number Publication date
EP2343318A2 (en) 2011-07-13
IL175608A0 (en) 2006-09-05
CN1890266B (zh) 2012-10-03
EP2343318A3 (en) 2013-02-27
TW200530267A (en) 2005-09-16
EP1687336A2 (en) 2006-08-09
KR20120108061A (ko) 2012-10-04
GB2408508A (en) 2005-06-01
GB0426043D0 (en) 2004-12-29
AU2004293180B2 (en) 2011-09-15
WO2005051998A3 (en) 2007-07-26
WO2005051998A2 (en) 2005-06-09
KR20060120161A (ko) 2006-11-24
RU2006122946A (ru) 2008-01-10
US8058016B2 (en) 2011-11-15
BRPI0417023A (pt) 2007-02-21
CA2547675A1 (en) 2005-06-09
AU2004293180A1 (en) 2005-06-09
NO20063026L (no) 2006-08-28
US20100061993A1 (en) 2010-03-11
UY28641A1 (es) 2005-06-30
JP4869074B2 (ja) 2012-02-01
CN1890266A (zh) 2007-01-03
JP2008502311A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
RU2013110876A (ru) Активируемые биспецифические антитела
ATE497508T1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
DE60032486D1 (de) Prion protein peptide und deren verwendung
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
AR046415A1 (es) Mimeticuerpos de nucleo de bisagra epo- mimeticos humanos, composiciones, metodos y usos
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
PE20050712A1 (es) Anticuerpos rg1
EA201270517A1 (ru) Микобактериальные вакцины
EA200700136A1 (ru) Анти-cd154-антитела
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
EA201100072A1 (ru) Новые композиции и способы
ATE544780T1 (de) Hybrid-polypeptide mit eingefügten sequenzmotiven und ihre verwendungen
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen

Legal Events

Date Code Title Description
FB Suspension of granting procedure